Xencor, Inc Marketable Securities, Unrealized Gain (Loss)
Xencor, Inc (XNCR) reported Marketable Securities, Unrealized Gain (Loss) of -$33.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-05
- Xencor, Inc marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was $18.06M.
- Xencor, Inc marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$51.93M, a 5618.49% decline year-over-year.
- Xencor, Inc marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $41.99M.
- Xencor, Inc marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $44.61M, a 1684.32% increase year-over-year.
- Xencor, Inc marketable securities, unrealized gain (loss) for fiscal 2025 was $87.13M.
- Xencor, Inc marketable securities, unrealized gain (loss) for fiscal 2024 was -$31.42M.
- Xencor, Inc marketable securities, unrealized gain (loss) for fiscal 2023 was -$395.00K.
- Xencor, Inc marketable securities, unrealized gain (loss) for fiscal 2022 was -$5.44M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 3 month as first filed | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 6 month as first filed | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 9 month as first filed | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$33.87M 10-Q · filed 2026-08-05 | $8.13M derived: sum of 3 quarters · filed 2026-08-05 | $52.73M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$51.93M 10-Q · filed 2026-05-06 | -$9.94M derived: sum of 2 quarters · filed 2026-05-06 | $34.67M derived: sum of 3 quarters · filed 2026-05-06 | $34.26M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $41.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $86.60M derived: sum of 2 quarters · filed 2026-02-25 | $86.19M derived: sum of 3 quarters · filed 2026-08-05 | $87.13M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $44.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $44.20M derived: sum of 2 quarters · filed 2026-08-05 | $45.14M 10-Q · filed 2025-11-05 | $14.16M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$413.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $528.00K 10-Q · filed 2026-08-05 | -$30.45M derived: sum of 3 quarters · filed 2026-08-05 | -$27.95M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $941.00K 10-Q · filed 2026-05-06 | $900.00K 10-Q · filed 2025-05-07 | -$30.03M derived: sum of 2 quarters · filed 2026-05-06 | -$27.53M derived: sum of 3 quarters · filed 2026-05-06 | -$28.03M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$30.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$28.47M derived: sum of 2 quarters · filed 2026-02-25 | -$28.97M derived: sum of 3 quarters · filed 2026-02-25 | -$31.42M 10-K · filed 2026-02-25 | -$1.95M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $2.50M 10-Q/A · filed 2025-02-24 | $2.00M derived: sum of 2 quarters · filed 2025-02-24 | -$448.00K 10-Q · filed 2025-11-05 | $500.00K 10-Q · filed 2024-11-06 | -$2.29M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | -$500.00K 10-Q/A · filed 2025-02-24 | -$9.70M 10-Q · filed 2025-08-06 | -$1.90M 10-Q · filed 2024-08-05 | -$4.79M derived: sum of 3 quarters · filed 2026-02-25 | -$3.60M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-07 | -$1.40M 10-Q · filed 2024-05-09 | -$4.29M derived: sum of 2 quarters · filed 2026-02-25 | -$3.10M derived: sum of 3 quarters · filed 2026-02-25 | -$1.29M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | -$6.59M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | -$5.39M derived: sum of 2 quarters · filed 2026-02-25 | -$3.60M derived: sum of 3 quarters · filed 2026-02-25 | -$395.00K 10-K · filed 2026-02-25 | $8.24M 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $1.20M 10-Q/A · filed 2025-02-24 | $1.15M 10-Q · filed 2023-11-08 | $3.00M derived: sum of 2 quarters · filed 2025-02-24 | $6.20M 10-Q/A · filed 2025-02-24 | $6.24M 10-Q · filed 2023-11-08 | $9.22M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $1.80M 10-Q/A · filed 2025-02-24 | $1.76M 10-Q · filed 2023-08-03 | $5.10M 10-Q/A · filed 2025-02-24 | $5.09M 10-Q · filed 2023-08-03 | $8.02M derived: sum of 3 quarters · filed 2025-02-27 | $7.09M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $3.30M 10-Q/A · filed 2025-02-24 | $3.33M 10-Q · filed 2023-05-08 | $6.22M derived: sum of 2 quarters · filed 2025-02-27 | $5.29M derived: sum of 3 quarters · filed 2025-02-27 | $3.47M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.99M derived: sum of 2 quarters · filed 2025-02-27 | $170.00K derived: sum of 3 quarters · filed 2025-02-27 | -$5.44M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$931.00K 10-Q · filed 2023-11-08 | -$2.75M derived: sum of 2 quarters · filed 2023-11-08 | -$8.37M 10-Q · filed 2023-11-08 | -$9.80M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2022-06-30 | -$1.82M 10-Q · filed 2023-08-03 | -$7.43M 10-Q · filed 2023-08-03 | -$8.87M derived: sum of 3 quarters · filed 2025-02-24 | -$8.93M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2022-03-31 | -$5.61M 10-Q · filed 2023-05-08 | -$7.05M derived: sum of 2 quarters · filed 2025-02-24 | -$7.11M derived: sum of 3 quarters · filed 2025-02-24 | -$7.22M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2021-12-31 | -$1.44M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-02-24 | -$1.49M derived: sum of 2 quarters · filed 2025-02-24 | -$1.61M derived: sum of 3 quarters · filed 2025-02-24 | -$1.58M 10-K/A · filed 2025-02-24 | ||||
| 2021-09-30 | -$59.00K 10-Q · filed 2022-11-07 | -$171.00K derived: sum of 2 quarters · filed 2022-11-07 | -$149.00K 10-Q · filed 2022-11-07 | -$641.00K derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | -$112.00K 10-Q · filed 2022-08-03 | -$90.00K 10-Q · filed 2022-08-03 | -$582.00K derived: sum of 3 quarters · filed 2023-02-27 | -$1.50M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $23.00K 10-Q · filed 2022-05-05 | -$470.00K derived: sum of 2 quarters · filed 2023-02-27 | -$1.39M derived: sum of 3 quarters · filed 2023-02-27 | -$959.00K derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | -$493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$1.41M derived: sum of 2 quarters · filed 2023-02-27 | -$982.00K derived: sum of 3 quarters · filed 2023-02-27 | -$1.09M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | -$916.00K 10-Q · filed 2021-11-08 | -$489.00K derived: sum of 2 quarters · filed 2021-11-08 | -$594.00K 10-Q · filed 2021-11-08 | -$869.00K derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $427.00K 10-Q · filed 2021-08-04 | $322.00K 10-Q · filed 2021-08-04 | $47.00K derived: sum of 3 quarters · filed 2022-02-24 | -$146.00K derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | -$105.00K 10-Q · filed 2021-05-05 | -$380.00K derived: sum of 2 quarters · filed 2022-02-24 | -$573.00K derived: sum of 3 quarters · filed 2022-02-24 | $711.00K derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | -$275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$468.00K derived: sum of 2 quarters · filed 2022-02-24 | $816.00K derived: sum of 3 quarters · filed 2022-02-24 | $2.13M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | -$193.00K 10-Q · filed 2020-11-06 | $1.09M derived: sum of 2 quarters · filed 2020-11-06 | $2.41M 10-Q · filed 2020-11-06 | $3.77M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $1.28M 10-Q · filed 2020-08-05 | $2.60M 10-Q · filed 2020-08-05 | $3.97M derived: sum of 3 quarters · filed 2021-02-24 | $3.64M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $1.32M 10-Q · filed 2020-05-08 | $2.68M derived: sum of 2 quarters · filed 2021-02-24 | $2.35M derived: sum of 3 quarters · filed 2021-02-24 | $2.55M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.04M derived: sum of 2 quarters · filed 2021-02-24 | $1.23M derived: sum of 3 quarters · filed 2021-02-24 | $837.00K 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | -$330.00K 10-Q · filed 2019-11-05 | -$137.00K derived: sum of 2 quarters · filed 2019-11-05 | -$530.00K 10-Q · filed 2019-11-05 | -$1.24M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $193.00K 10-Q · filed 2019-08-07 | -$200.00K 10-Q · filed 2019-08-07 | -$911.00K derived: sum of 3 quarters · filed 2020-02-25 | -$768.00K derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | -$393.00K 10-Q · filed 2019-05-09 | -$1.10M derived: sum of 2 quarters · filed 2020-02-25 | -$961.00K derived: sum of 3 quarters · filed 2020-02-25 | -$1.00M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | -$711.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$568.00K derived: sum of 2 quarters · filed 2020-02-25 | -$612.00K derived: sum of 3 quarters · filed 2020-02-25 | -$367.00K 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $143.00K 10-Q · filed 2018-11-05 | $99.00K derived: sum of 2 quarters · filed 2018-11-05 | $344.00K 10-Q · filed 2018-11-05 | -$847.00K derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-06-30 | -$44.00K 10-Q · filed 2018-08-07 | $201.00K 10-Q · filed 2018-08-07 | -$990.00K derived: sum of 3 quarters · filed 2019-02-26 | -$1.46M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-03-31 | $245.00K 10-Q · filed 2018-05-07 | -$946.00K derived: sum of 2 quarters · filed 2019-02-26 | -$1.41M derived: sum of 3 quarters · filed 2019-02-26 | -$1.30M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2016-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$1.66M derived: sum of 2 quarters · filed 2019-02-26 | -$1.54M derived: sum of 3 quarters · filed 2019-02-26 | -$925.00K 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | -$466.00K 10-Q · filed 2017-11-08 | -$353.00K derived: sum of 2 quarters · filed 2017-11-08 | $266.00K 10-Q · filed 2017-11-08 | -$244.00K derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-06-30 | $113.00K 10-Q · filed 2017-08-07 | $732.00K 10-Q · filed 2017-08-07 | $222.00K derived: sum of 3 quarters · filed 2018-02-28 | $306.00K derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-03-31 | $619.00K 10-Q · filed 2017-05-10 | $109.00K derived: sum of 2 quarters · filed 2018-02-28 | $193.00K derived: sum of 3 quarters · filed 2018-02-28 | $138.00K derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-12-31 | -$510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$426.00K derived: sum of 2 quarters · filed 2018-02-28 | -$481.00K derived: sum of 3 quarters · filed 2018-02-28 | -$516.00K 10-K · filed 2018-02-28 | ||||
| 2015-09-30 | $84.00K 10-Q · filed 2016-11-02 | $29.00K derived: sum of 2 quarters · filed 2016-11-02 | -$6.00K 10-Q · filed 2016-11-02 | |||||
| 2015-06-30 | -$55.00K 10-Q · filed 2016-08-03 | -$90.00K 10-Q · filed 2016-08-03 | ||||||
| 2015-03-31 | -$35.00K 10-Q · filed 2016-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |